JPWO2017090570A1 - Treatment method for medical waste containers - Google Patents
Treatment method for medical waste containers Download PDFInfo
- Publication number
- JPWO2017090570A1 JPWO2017090570A1 JP2017552409A JP2017552409A JPWO2017090570A1 JP WO2017090570 A1 JPWO2017090570 A1 JP WO2017090570A1 JP 2017552409 A JP2017552409 A JP 2017552409A JP 2017552409 A JP2017552409 A JP 2017552409A JP WO2017090570 A1 JPWO2017090570 A1 JP WO2017090570A1
- Authority
- JP
- Japan
- Prior art keywords
- medical waste
- chlorine dioxide
- solution
- waste container
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002906 medical waste Substances 0.000 title claims abstract description 82
- 238000000034 method Methods 0.000 title claims abstract description 62
- OSVXSBDYLRYLIG-UHFFFAOYSA-N dioxidochlorine(.) Chemical compound O=Cl=O OSVXSBDYLRYLIG-UHFFFAOYSA-N 0.000 claims abstract description 216
- 239000004155 Chlorine dioxide Substances 0.000 claims abstract description 108
- 235000019398 chlorine dioxide Nutrition 0.000 claims abstract description 108
- 239000007788 liquid Substances 0.000 claims abstract description 53
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 41
- 244000005700 microbiome Species 0.000 claims abstract description 39
- 229910001919 chlorite Inorganic materials 0.000 claims abstract description 27
- 229910052619 chlorite group Inorganic materials 0.000 claims abstract description 27
- QBWCMBCROVPCKQ-UHFFFAOYSA-N chlorous acid Chemical compound OCl=O QBWCMBCROVPCKQ-UHFFFAOYSA-N 0.000 claims abstract description 24
- 239000000203 mixture Substances 0.000 claims abstract description 7
- 238000005507 spraying Methods 0.000 claims description 13
- 208000015181 infectious disease Diseases 0.000 claims description 12
- 230000002458 infectious effect Effects 0.000 claims description 7
- 238000009792 diffusion process Methods 0.000 claims description 4
- 238000003672 processing method Methods 0.000 claims 8
- 238000013268 sustained release Methods 0.000 abstract 1
- 239000012730 sustained-release form Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 71
- 239000007789 gas Substances 0.000 description 56
- 241000700605 Viruses Species 0.000 description 25
- 238000002474 experimental method Methods 0.000 description 14
- 230000000694 effects Effects 0.000 description 10
- 239000002699 waste material Substances 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 9
- UKLNMMHNWFDKNT-UHFFFAOYSA-M sodium chlorite Chemical compound [Na+].[O-]Cl=O UKLNMMHNWFDKNT-UHFFFAOYSA-M 0.000 description 9
- 229960002218 sodium chlorite Drugs 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 238000009434 installation Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 241000714201 Feline calicivirus Species 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 5
- -1 alkali metal chlorite Chemical class 0.000 description 5
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 5
- 235000019799 monosodium phosphate Nutrition 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000000645 desinfectant Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000003002 pH adjusting agent Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 241000709687 Coxsackievirus Species 0.000 description 2
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 2
- 208000030820 Ebola disease Diseases 0.000 description 2
- 208000032163 Emerging Communicable disease Diseases 0.000 description 2
- 241000709661 Enterovirus Species 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241001263478 Norovirus Species 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001877 deodorizing effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- VISKNDGJUCDNMS-UHFFFAOYSA-M potassium;chlorite Chemical compound [K+].[O-]Cl=O VISKNDGJUCDNMS-UHFFFAOYSA-M 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 2
- 235000019345 sodium thiosulphate Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241000589291 Acinetobacter Species 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- 241000238421 Arthropoda Species 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 241000588923 Citrobacter Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241000193155 Clostridium botulinum Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- 241001466953 Echovirus Species 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 241000701460 JC polyomavirus Species 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 241000712902 Lassa mammarenavirus Species 0.000 description 1
- 241000555676 Malassezia Species 0.000 description 1
- 241001115401 Marburgvirus Species 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
- 208000025370 Middle East respiratory syndrome Diseases 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 241000150350 Peribunyaviridae Species 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 241000702247 Reoviridae Species 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000369757 Sapovirus Species 0.000 description 1
- 241001529934 Simian T-lymphotropic virus 3 Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000893966 Trichophyton verrucosum Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 241000607272 Vibrio parahaemolyticus Species 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- ISFLYIRWQDJPDR-UHFFFAOYSA-L barium chlorate Chemical compound [Ba+2].[O-]Cl(=O)=O.[O-]Cl(=O)=O ISFLYIRWQDJPDR-UHFFFAOYSA-L 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- QXIKMJLSPJFYOI-UHFFFAOYSA-L calcium;dichlorite Chemical compound [Ca+2].[O-]Cl=O.[O-]Cl=O QXIKMJLSPJFYOI-UHFFFAOYSA-L 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical compound OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- KAGBQTDQNWOCND-UHFFFAOYSA-M lithium;chlorite Chemical compound [Li+].[O-]Cl=O KAGBQTDQNWOCND-UHFFFAOYSA-M 0.000 description 1
- NWAPVVCSZCCZCU-UHFFFAOYSA-L magnesium;dichlorite Chemical compound [Mg+2].[O-]Cl=O.[O-]Cl=O NWAPVVCSZCCZCU-UHFFFAOYSA-L 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 244000309711 non-enveloped viruses Species 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 229940005657 pyrophosphoric acid Drugs 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L11/00—Methods specially adapted for refuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
- A61L2/20—Gaseous substances, e.g. vapours
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B09—DISPOSAL OF SOLID WASTE; RECLAMATION OF CONTAMINATED SOIL
- B09B—DISPOSAL OF SOLID WASTE NOT OTHERWISE PROVIDED FOR
- B09B3/00—Destroying solid waste or transforming solid waste into something useful or harmless
- B09B3/0075—Disposal of medical waste
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
- B65B55/00—Preserving, protecting or purifying packages or package contents in association with packaging
- B65B55/02—Sterilising, e.g. of complete packages
- B65B55/04—Sterilising wrappers or receptacles prior to, or during, packaging
- B65B55/10—Sterilising wrappers or receptacles prior to, or during, packaging by liquids or gases
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B11/00—Oxides or oxyacids of halogens; Salts thereof
- C01B11/02—Oxides of chlorine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2202/00—Aspects relating to methods or apparatus for disinfecting or sterilising materials or objects
- A61L2202/20—Targets to be treated
- A61L2202/23—Containers, e.g. vials, bottles, syringes, mail
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2202/00—Aspects relating to methods or apparatus for disinfecting or sterilising materials or objects
- A61L2202/20—Targets to be treated
- A61L2202/24—Medical instruments, e.g. endoscopes, catheters, sharps
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Mechanical Engineering (AREA)
- Environmental & Geological Engineering (AREA)
- Apparatus For Disinfection Or Sterilisation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Processing Of Solid Wastes (AREA)
- Disinfection, Sterilisation Or Deodorisation Of Air (AREA)
- Feeding, Discharge, Calcimining, Fusing, And Gas-Generation Devices (AREA)
Abstract
【課題】
有害微生物を含み得る医療廃棄物を、医療廃棄物容器内において安全かつ簡便に処理する方法を提供する。
【解決手段】
有害微生物を伴う医療廃棄物を含む医療廃棄物容器の処理方法であって、前記医療廃棄物容器内に二酸化塩素ガスおよび亜塩素酸塩を含む液剤を適用する工程を含み、前記液剤は、前記二酸化塩素ガスを徐放放出する組成を備えることを特徴とする、方法を提供する。
【選択図】図7
【Task】
Provided is a method for safely and simply treating medical waste that may contain harmful microorganisms in a medical waste container.
[Solution]
A method for treating a medical waste container containing medical waste accompanied by harmful microorganisms, comprising a step of applying a liquid agent containing chlorine dioxide gas and chlorite in the medical waste container, Provided is a method characterized by comprising a composition for sustained release of chlorine dioxide gas.
[Selection] Figure 7
Description
本発明は、二酸化塩素ガスおよび亜塩素酸塩を含む液剤を用いた、有害微生物を伴う医療廃棄物を含む医療廃棄物容器の処理方法に関する。 The present invention relates to a method for treating a medical waste container containing medical waste accompanied by harmful microorganisms using a liquid agent containing chlorine dioxide gas and chlorite.
近年、エボラ出血熱や新型インフルエンザ等の新興・再興感染症が世界各地で発生し、大きな問題となっている。これらの感染症の患者が接触した廃棄物(例えば、患者の体液が付着した布やティッシュペーパー)や、これらの患者の治療のために使用された医療器具(例えば、注射器)等は、感染源となり得るため、医療廃棄物として適切に処理される必要がある。 In recent years, emerging and re-emerging infectious diseases such as Ebola hemorrhagic fever and new influenza have occurred in various parts of the world and have become major problems. Wastes contacted by patients with these infections (for example, cloth or tissue paper with the patient's bodily fluid), medical devices used to treat these patients (for example, syringes), etc. Therefore, it needs to be properly treated as medical waste.
医療廃棄物は人や動物に感染する病原体等を含み得るため、一般の廃棄物よりも高度な管理の下、処理される必要がある。一般的に、医療廃棄物は専用の医療廃棄物容器に廃棄/保存された後に、焼却またはオートクレーブ等による滅菌がなされるか、専門業者による回収/処理が行われる。しかし、医療廃棄物容器内で増殖した病原体、あるいは、医療廃棄物容器の入口付近に付着した病原体が医療廃棄物容器外へ拡散し、医療廃棄物容器の取り扱いの際に感染のリスクとなる可能性が常に存在する。 Since medical waste can include pathogens that infect humans and animals, it needs to be treated under higher control than general waste. Generally, medical waste is disposed / stored in a dedicated medical waste container and then sterilized by incineration or autoclave, or collected / processed by a specialist. However, pathogens that grow in medical waste containers or that adhere to the vicinity of the entrance of medical waste containers can spread out of the medical waste containers, creating a risk of infection when handling medical waste containers. Sex always exists.
多くの実験室や医療機関において、有害微生物を不活化させるために、アルコール系の薬剤での清拭あるいは噴霧による消毒が実施されている。揮発したアルコールの殺菌能力は低いため、汎用されるアルコール系の薬剤では薬液が対象となる微生物に直接接触することが、その効果を発揮するために不可欠となる。すなわち、アルコール系の薬剤を用いた消毒方法では、薬剤が直接接触しない箇所に付着している微生物の消毒が困難であった(例えば、対象が複雑な三次的形状をした医療廃棄物の場合、等)。 In many laboratories and medical institutions, in order to inactivate harmful microorganisms, disinfection by wiping or spraying with an alcohol-based drug is performed. Since the sterilizing ability of the volatilized alcohol is low, it is indispensable for the drug solution to be in direct contact with the target microorganism in order to exert its effect in the alcohol-based chemicals that are widely used. That is, in the disinfection method using an alcohol-based drug, it is difficult to disinfect microorganisms adhering to a place where the drug is not in direct contact (for example, in the case of medical waste having a complicated tertiary shape, etc).
二酸化塩素ガスは、低濃度では動物の生体に対して安全なガスである一方、そのような低濃度でも、細菌・真菌・ウイルス等の微生物に対する失活作用や、消臭作用等を有していることが知られている。二酸化塩素を用いた医療廃棄物の処理方法はこれまでも提案されているが、医療廃棄物の隅々まで二酸化塩素の消毒効果を浸透させるためには、持続的に二酸化塩素に曝露させる必要があり、そのためには大掛かりな装置が必要であったり(例えば、特許文献1、特許文献2)、医療廃棄物を粉砕して二酸化塩素を含む消毒液に浸漬させる必要がある(例えば、特許文献3)等、汎用性には乏しいものであった。 Chlorine dioxide gas is a safe gas for animal bodies at low concentrations, but even at such low concentrations, it has a deactivating effect and a deodorizing effect on bacteria such as bacteria, fungi, and viruses. It is known that The treatment method of medical waste using chlorine dioxide has been proposed so far, but in order to penetrate the disinfection effect of chlorine dioxide to every corner of medical waste, it is necessary to continuously expose to chlorine dioxide. For this purpose, a large-scale device is required (for example, Patent Document 1 and Patent Document 2), or medical waste must be pulverized and immersed in a disinfectant containing chlorine dioxide (for example, Patent Document 3). ) Etc., it was poor in versatility.
上述のとおり、これまで、有害微生物を含み得る医療廃棄物を、医療廃棄物容器内において安全かつ簡便に処理する方法は、提供されてこなかった。 As described above, a method for safely and simply treating medical waste that may contain harmful microorganisms in a medical waste container has not been provided so far.
本発明者らは、二酸化塩素を含む溶液の性質について研究していたところ、二酸化塩素ガスおよび亜塩素酸塩を含む溶液を空間へ適用すると、驚くべきことに、二酸化塩素ガスのみを溶存させた溶液を空間へ適用する場合と比較して、空間中の二酸化塩素ガス濃度が極めて長時間維持されるという性質を発見した(本願の実施例1を参照のこと)。 The present inventors have studied the properties of a solution containing chlorine dioxide, and surprisingly, when a solution containing chlorine dioxide gas and chlorite was applied to the space, only chlorine dioxide gas was dissolved. It has been found that the chlorine dioxide gas concentration in the space is maintained for a very long time compared to the case where the solution is applied to the space (see Example 1 of the present application).
そして、本発明者らは、二酸化塩素ガスおよび亜塩素酸塩を含む溶液の上記性質を利用することにより、医療廃棄物を含む医療廃棄物容器を簡便に、且つ、安全に処理することができることを見出し、本発明を完成させるに到った。 And the present inventors can process a medical waste container containing medical waste simply and safely by utilizing the above properties of a solution containing chlorine dioxide gas and chlorite. As a result, the present invention has been completed.
すなわち本発明の方法は、一実施態様において、有害微生物を伴う医療廃棄物を含む医療廃棄物容器の処理方法であって、前記医療廃棄物容器内に二酸化塩素ガスおよび亜塩素酸塩を含む液剤を適用する工程を含み、前記液剤は、前記二酸化塩素ガスを徐放放出する組成を備えることを特徴とする、方法に関する。 That is, in one embodiment, the method of the present invention is a method for treating a medical waste container containing medical waste accompanied by harmful microorganisms, wherein the medical waste container contains a liquid solution containing chlorine dioxide gas and chlorite. The liquid agent is provided with a composition that releases the chlorine dioxide gas gradually, and relates to a method.
また、本発明の方法は、一実施態様において、前記液剤の組成として、前記液剤には、10〜2000ppmの二酸化塩素ガス、0.05重量%〜10重量%の亜塩素酸塩の濃度が含まれており、かつ、前記液剤のpHは4.5〜6.5の範囲内に調製されていることを特徴とする。 In one embodiment of the method of the present invention, as the composition of the liquid agent, the liquid agent includes 10 to 2000 ppm of chlorine dioxide gas and 0.05 to 10% by weight of chlorite. And the pH of the solution is adjusted within the range of 4.5 to 6.5.
また、本発明の方法は、一実施態様において、前記液剤の適用が、前記液剤の医療廃棄物容器内への噴霧または、前記液剤を含む容器の医療廃棄物容器内への設置によることを特徴とする。 In one embodiment, the method of the present invention is characterized in that the application of the liquid is performed by spraying the liquid into a medical waste container or installing a container containing the liquid into the medical waste container. And
また、本発明の方法は、一実施態様において、前記有害微生物が感染性微生物であることを特徴とする。 In one embodiment, the method of the present invention is characterized in that the harmful microorganism is an infectious microorganism.
また、本発明の方法は、一実施態様において、前記液剤が、50〜1000ppmの二酸化塩素ガスを含むことを特徴とする。 Moreover, the method of this invention is characterized by the said liquid agent containing 50-1000 ppm chlorine dioxide gas in one embodiment.
また、本発明の方法は、一実施態様において、前記液剤が、0.1重量%〜5.0重量%の亜塩素酸塩を含むことを特徴とする。 Moreover, the method of this invention is characterized by the said liquid agent containing 0.1 weight%-5.0 weight% chlorite in one embodiment.
また、本発明の方法は、一実施態様において、前記液剤のpHが、5.5〜6.0の範囲内であることを特徴とする。 Moreover, the method of this invention is characterized by the pH of the said liquid agent being in the range of 5.5-6.0 in one embodiment.
また、本発明の方法は、一実施態様において、前記液剤の適用が、少なくとも一部の前記有害微生物に対し、前記液剤が直接的に接触しないことを特徴とする。 In one embodiment, the method of the present invention is characterized in that the liquid agent is not in direct contact with at least a part of the harmful microorganisms.
また、本発明の方法は、一実施態様において、前記液剤の適用が、すべての前記有害微生物に対し、前記液剤が直接的に接触しないことを特徴とする。 In one embodiment, the method of the present invention is characterized in that the solution is not in direct contact with all harmful microorganisms.
また、本発明の方法は、一実施態様において、前記処理が、前記有害微生物の拡散を低減することを特徴とする。 In one embodiment, the method of the present invention is characterized in that the treatment reduces diffusion of the harmful microorganisms.
なお、上記に挙げた本発明の一又は複数の特徴を任意に組み合わせた発明も、本発明の範囲に含まれる。 Note that an invention in which one or more features of the present invention listed above are arbitrarily combined is also included in the scope of the present invention.
本願の実施例においても示されているとおり、本発明の方法に用いられる液剤が医療廃棄物容器内に適用されると、医療廃棄物内の二酸化塩素ガス濃度が、長時間高く保たれる。そのため、本発明の方法によれば、医療廃棄物容器内の医療廃棄物の隅々まで二酸化塩素ガスに曝露されるため、医療廃棄物に付着した有害微生物を効率よく処理することができ、医療廃棄物容器からの有害微生物の拡散を低減させることができる。すなわち、本発明の方法においては、適用する液剤が、医療廃棄物に付着した有害微生物の一部に直接的には接触しなくとも(あるいは、適用した液剤が医療廃棄物に付着した微生物に直接的には全く接触しなくとも)、医療廃棄物容器内の実質的に全ての有害微生物に消毒効果を及ぼすことができる。 As also shown in the examples of the present application, when the liquid used in the method of the present invention is applied to a medical waste container, the chlorine dioxide gas concentration in the medical waste is kept high for a long time. Therefore, according to the method of the present invention, since every corner of the medical waste in the medical waste container is exposed to chlorine dioxide gas, harmful microorganisms attached to the medical waste can be treated efficiently, The diffusion of harmful microorganisms from the waste container can be reduced. That is, in the method of the present invention, the applied liquid agent does not directly contact a part of the harmful microorganisms attached to the medical waste (or the applied liquid agent is directly applied to the microorganisms attached to the medical waste. Disinfectant effect on virtually all harmful microorganisms in the medical waste container.
すなわち本発明は、有害微生物を含み得る医療廃棄物を、医療廃棄物容器内において安全かつ簡便に処理する方法を提供する。 That is, the present invention provides a method for safely and simply treating medical waste that may contain harmful microorganisms in a medical waste container.
本発明は、有害微生物を伴う医療廃棄物を含む医療廃棄物容器の処理方法に関する。 The present invention relates to a method for treating a medical waste container containing medical waste accompanied by harmful microorganisms.
本明細書における医療廃棄物とは、医療行為に関係して排出される廃棄物に限定されず、感染症の感染源となりうるあらゆる廃棄物を含む。例えば、医療行為に使用した器具(例えば、注射針、注射筒、手袋、マスク、等)、生物学的実験に使用した器具等(例えば、微生物の付着したシャーレ、培地、マイクロチップ、等)、感染症患者の血液や体液の付着した紙や布巾、等も本明細書における医療廃棄物に含まれる。 The medical waste in this specification is not limited to the waste discharged in relation to medical practice, but includes any waste that can be a source of infection. For example, instruments used in medical practice (eg, needles, syringes, gloves, masks, etc.), instruments used in biological experiments (eg, petri dishes, culture media, microchips, etc.) Papers and cloths to which blood and body fluids of infectious patients are attached are also included in the medical waste in this specification.
本明細書における医療廃棄物容器とは、医療廃棄物を収納する容器であって、その形状・構造は特に限定されない。感染性微生物の拡散防止の観点から、本発明の適用対象となる医療廃棄物容器は気密性が高いものが好ましいが、完全な気密性を有していなくとも、ある程度閉鎖的な構造であれば、本発明を好適に適用することができる。また、本発明の方法は、各コンパートメントが流体的に連通している限り、複数のコンパートメントを有する医療廃棄物容器にも適用することができる(各コンパートメントがそれぞれ流体的に連通していない場合には、それぞれのコンパートメントに本発明の方法に適用することにより、目的の効果を得ることができる)。 The medical waste container in this specification is a container for storing medical waste, and its shape and structure are not particularly limited. From the viewpoint of preventing the spread of infectious microorganisms, it is preferable that the medical waste container to which the present invention is applied be highly airtight. The present invention can be preferably applied. The method of the present invention can also be applied to a medical waste container having a plurality of compartments as long as each compartment is in fluid communication (when each compartment is not in fluid communication). Can be obtained by applying the method of the present invention to each compartment).
本発明の方法は、医療廃棄物容器内に二酸化塩素ガスおよび亜塩素酸塩を含む液剤を適用する工程を含む。本発明の方法において用いられる液剤は、10〜2000ppmの二酸化塩素ガス、0.05重量%〜10重量%の亜塩素酸塩の濃度が含まれており、かつ、前記液剤のpHは4.5〜6.5の範囲内に調製されている液剤であることが好ましい。好ましくは、液剤中に含まれる二酸化塩素ガス濃度は50〜1000ppmであってよく、より好ましくは、100〜600ppmであってよい。また、好ましくは、液剤中に含まれる亜塩素酸塩の濃度は0.1重量%〜5.0重量%であってよく、より好ましくは0.5重量%〜2.5重量%であってよい。液剤のpHが4.5よりも低くなると、液剤中の亜塩素酸塩が過剰に反応し、二酸化塩素ガスを放出するため、二酸化塩素ガス放出量のコントロールが難しくなり、また、液剤の保存安定性が低下する。また、液剤のpHが6.5よりも高くなると、液剤中の亜塩素酸塩の反応性が低下し、適切な量の二酸化塩素ガスが放出されなくなる。液剤のpHは5.5〜6.0の範囲内であることがより好ましい。なお、液剤中の二酸化塩素ガス濃度、亜塩素酸塩濃度、および、pHは、上記の範囲で任意に組み合わせることができる。 The method of the present invention includes the step of applying a solution comprising chlorine dioxide gas and chlorite in a medical waste container. The liquid used in the method of the present invention contains 10 to 2000 ppm of chlorine dioxide gas, 0.05 wt% to 10 wt% chlorite concentration, and the pH of the liquid is 4.5. It is preferable that it is the liquid agent prepared in the range of -6.5. Preferably, the concentration of chlorine dioxide gas contained in the liquid agent may be 50 to 1000 ppm, more preferably 100 to 600 ppm. Preferably, the concentration of chlorite contained in the solution may be 0.1 wt% to 5.0 wt%, more preferably 0.5 wt% to 2.5 wt%. Good. If the pH of the solution is lower than 4.5, the chlorite in the solution reacts excessively and releases chlorine dioxide gas, making it difficult to control the amount of chlorine dioxide gas released, and the storage stability of the solution Sex is reduced. Moreover, when the pH of a liquid agent becomes higher than 6.5, the reactivity of the chlorite in a liquid agent will fall, and an appropriate amount of chlorine dioxide gas will not be discharge | released. The pH of the liquid agent is more preferably in the range of 5.5 to 6.0. In addition, the chlorine dioxide gas density | concentration in a liquid agent, a chlorite density | concentration, and pH can be arbitrarily combined in said range.
本発明の方法において用いられる液剤は、例えば、次のように製造することができる。まず、(a)亜塩素酸塩を水に溶解して2000〜180000ppmの亜塩素酸塩水溶液を調製し、(b)二酸化塩素ガスを溶解させ100〜2900ppmの二酸化塩素水溶液を調製し、そして、(a)および(b)を混合した後、この溶液に、pH調整剤を混合して二酸化塩素液剤とする。なお、上記の製造方法における、亜塩素酸塩水溶液の濃度、二酸化塩素水溶液の濃度は、目的とする液剤の組成に応じて、当業者が適宜調節することができる。 The liquid agent used in the method of the present invention can be produced, for example, as follows. First, (a) chlorite is dissolved in water to prepare 2000-18000 ppm chlorite aqueous solution, (b) chlorine dioxide gas is dissolved to prepare 100-2900 ppm chlorine dioxide aqueous solution, and After mixing (a) and (b), a pH adjuster is mixed with this solution to obtain a chlorine dioxide solution. In addition, the concentration of the chlorite aqueous solution and the concentration of the chlorine dioxide aqueous solution in the above production method can be appropriately adjusted by those skilled in the art according to the composition of the target liquid agent.
上記のような方法によって液剤を調整することにより、液剤中の溶存二酸化塩素濃度を高濃度から低濃度まで自由に調節することができる。また、本発明の方法に用いられる液剤は、二酸化塩素ガスと亜塩素酸塩を含むため、液剤から空気中に二酸化塩素ガスが放出されると、液剤中に二酸化塩素ガス濃度が低下するが、化学平衡により、亜塩素酸塩から二酸化塩素が液剤中に供給され、結果として液剤中の二酸化塩素ガス濃度が略一定に保たれる。この効果により、本発明において用いられる液剤は、長時間に渡って、徐放的に二酸化塩素ガスを空気中に放出することができる。また、液剤のpHが4.5〜6.5の範囲内に調製されていると、液剤からの二酸化塩素ガスの放出量と、亜塩素酸塩からの二酸化塩素の供給のバランスが好適に保たれるため、より長時間、略一定の濃度の二酸化塩素ガスを放出することができる。 By adjusting the liquid agent by the method as described above, the dissolved chlorine dioxide concentration in the liquid agent can be freely adjusted from a high concentration to a low concentration. Moreover, since the liquid agent used in the method of the present invention contains chlorine dioxide gas and chlorite, when chlorine dioxide gas is released into the air from the liquid agent, the chlorine dioxide gas concentration in the liquid agent decreases, Due to chemical equilibrium, chlorine dioxide is supplied from the chlorite into the liquid, and as a result, the chlorine dioxide gas concentration in the liquid is kept substantially constant. Due to this effect, the liquid agent used in the present invention can release chlorine dioxide gas into the air gradually over a long period of time. In addition, when the pH of the solution is adjusted within the range of 4.5 to 6.5, the balance between the amount of chlorine dioxide gas released from the solution and the supply of chlorine dioxide from chlorite is suitably maintained. Therefore, chlorine dioxide gas having a substantially constant concentration can be released for a longer time.
本発明の方法おいて用いられる液剤に含まれる亜塩素酸塩としては、例えば、亜塩素酸アルカリ金属塩や亜塩素酸アルカリ土類金属塩が挙げられる。亜塩素酸アルカリ金属塩としては、例えば亜塩素酸ナトリウム、亜塩素酸カリウム、亜塩素酸リチウムが挙げられ、亜塩素酸アルカリ土類金属塩としては、亜塩素酸カルシウム、亜塩素酸マグネシウム、亜塩素酸バリウムが挙げられる。なかでも、入手が容易という点から、亜塩素酸ナトリウム、亜塩素酸カリウムが好ましく、亜塩素酸ナトリウムが最も好ましい。これら亜塩素酸塩は1種を単独で用いてもよいし、2種以上を併用しても構わない。 Examples of the chlorite contained in the liquid used in the method of the present invention include an alkali metal chlorite and an alkaline earth metal chlorite. Examples of the alkali metal chlorite include sodium chlorite, potassium chlorite, and lithium chlorite. Examples of the alkaline earth metal chlorite include calcium chlorite, magnesium chlorite, Barium chlorate is mentioned. Of these, sodium chlorite and potassium chlorite are preferable and sodium chlorite is most preferable from the viewpoint of easy availability. These chlorites may be used individually by 1 type, and may use 2 or more types together.
本発明の方法において用いられる液剤を調製するためのpH調整剤は、当業者が任意のものを用いることができるが、例えば、リン酸、ホウ酸、メタリン酸、ピロリン酸、スルファミン酸、酢酸、クエン酸やそれらの塩などを用いることができ、優れた保存安定性が得られるという点で無機酸またはその塩が好ましい。なかでも、保存安定性に優れ、保存中における液性(pH)の変動を最小限に抑えることができ、それにより優れた殺菌作用、抗ウイルス作用、防カビ作用、防臭作用などの効果を発揮することができるという点で、リン酸またはその塩(例えば、リン酸二水素ナトリウム、リン酸二水素ナトリウムとリン酸水素二ナトリウムの混合物、等)を使用することが好ましく、リン酸二水素ナトリウムを使用することがさらに好ましい。なお、pH調整剤は、1種を単独で使用してもよいし、2種以上を併用してもよい。 A person skilled in the art can use any pH adjusting agent for preparing the liquid used in the method of the present invention. For example, phosphoric acid, boric acid, metaphosphoric acid, pyrophosphoric acid, sulfamic acid, acetic acid, Citric acid or a salt thereof can be used, and an inorganic acid or a salt thereof is preferable in that excellent storage stability can be obtained. In particular, it has excellent storage stability and can minimize fluctuations in liquidity (pH) during storage, thereby exhibiting excellent bactericidal, antiviral, antifungal, and deodorizing effects. It is preferable to use phosphoric acid or a salt thereof (for example, sodium dihydrogen phosphate, a mixture of sodium dihydrogen phosphate and disodium hydrogen phosphate, etc.), and sodium dihydrogen phosphate. More preferably, is used. In addition, a pH adjuster may be used individually by 1 type, and may use 2 or more types together.
本発明の方法において、液剤を医療廃棄物容器内に適用する方法は任意であり、例えば、前記液剤を医療廃棄物容器内への噴霧することによって適用してもよく、また、前記液剤を含む容器を医療廃棄物容器内への設置することによって適用してもよい。適用してすぐに効果が発揮され、効果が比較的長時間持続するという観点からは、液剤を噴霧によって適用することがより好ましい。 In the method of the present invention, the method of applying the liquid agent into the medical waste container is arbitrary. For example, the liquid agent may be applied by spraying the medical agent into the medical waste container and includes the liquid agent. You may apply by installing a container in a medical waste container. From the viewpoint that the effect is exhibited immediately after application and the effect lasts for a relatively long time, it is more preferable to apply the solution by spraying.
なお、本願の実施例においても示されているとおり、本発明の方法に用いられる液剤が医療廃棄物容器内に適用されると、医療廃棄物内の二酸化塩素ガス濃度が、長時間高く保たれる。そのため、本発明の方法によれば、医療廃棄物容器内の医療廃棄物の隅々まで二酸化塩素ガスに曝露されるため、医療廃棄物に付着した有害微生物を効率よく処理することができ、医療廃棄物容器からの有害微生物の拡散を低減させることができる。すなわち、本発明の方法においては、適用する液剤が、医療廃棄物に付着した有害微生物の一部に直接的には接触しなくとも(あるいは、適用した液剤が医療廃棄物に付着した微生物に直接的には全く接触しなくとも)、医療廃棄物容器内の実質的に全ての有害微生物に消毒効果を及ぼすことができる。 As also shown in the examples of the present application, when the liquid used in the method of the present invention is applied in a medical waste container, the chlorine dioxide gas concentration in the medical waste is kept high for a long time. It is. Therefore, according to the method of the present invention, since every corner of the medical waste in the medical waste container is exposed to chlorine dioxide gas, harmful microorganisms attached to the medical waste can be treated efficiently, The diffusion of harmful microorganisms from the waste container can be reduced. That is, in the method of the present invention, the applied liquid agent does not directly contact a part of the harmful microorganisms attached to the medical waste (or the applied liquid agent is directly applied to the microorganisms attached to the medical waste. Disinfectant effect on virtually all harmful microorganisms in the medical waste container.
本発明の方法における有害微生物とは、ヒトや動物に悪影響を与え得る微生物を広く含み、特に、ヒトや動物に感染性を有する微生物を含む。例えば、本発明における有害微生物には、ウイルス、細菌、真菌、古細菌、および、寄生生物(例えば、寄生虫、寄生性の節足動物)、感染性のタンパク質(例えば、異常プリオンタンパク)が含まれる。本発明の方法を適用可能なウイルスとしては、エンベロープのあるウイルスあるいはエンベロープのないウイルス、例えば、水痘・帯状疱疹ウイルス、インフルエンザウイルス(ヒト、鳥、豚など)、単純性疱疹ウイルス、アデノウイルス、エンテロウイルス、ライノウイルス、ヒトパピローマウイルス(ヒト乳頭種ウイルス)、ポックスウイルス、コクサッキーウイルス、単純ヘルペスウイルス、サイトメガロウイルス、EBウイルス、アデノウイルス、パピローマウイルス、JCウイルス、パルボウイルス、B型肝炎ウイルス、C型肝炎ウイルス、ラッサウイルス、ネコカリシウイルス、ノロウイルス、サポウイルス、コロナウイルス、SARSウイルス、風疹ウイルス、ムンプスウイルス、麻疹ウイルス、RSウイルス、ポリオウイルス、コクサッキーウイルス、エコーウイルス、マールブルグウイルス、エボラウイルス、黄熱病ウイルス、ブンヤウイルス科のウイルス、狂犬病ウイルス、レオウイルス科のウイルス、ロタウイルス、ヒト免疫不全ウイルス、ヒトTリンパ好性ウイルス、サル免疫不全ウイルス、STLVなどが挙げられる。また、本発明の方法を適用可能な細菌としてはグラム陽性菌あるいはグラム陰性菌、例えば、黄色ブドウ球菌、緑膿菌、大腸菌、連鎖球菌、淋菌、梅毒菌、髄膜炎菌、結核菌、抗酸菌、クレブシエラ(肺炎桿菌)、サルモネラ菌、ボツリヌス菌、プロテウス、百日咳菌、セラチア菌、腸炎ビブリオ菌、シトロバクター、アシネトバクター、カンピロバクター、エンテロバクター、マイコプラズマ、クラミジア、クロストリジウムなどが挙げられる。さらに、本発明の方法を適用可能な真菌としては、例えば、アスペルギルス、白癬菌、マラセチア菌、カンジダなどが挙げられる。 The harmful microorganisms in the method of the present invention widely include microorganisms that can adversely affect humans and animals, and particularly include microorganisms that are infectious to humans and animals. For example, harmful microorganisms in the present invention include viruses, bacteria, fungi, archaea, parasites (eg, parasites, parasitic arthropods), and infectious proteins (eg, abnormal prion proteins). It is. Viruses to which the method of the present invention can be applied include enveloped or non-enveloped viruses such as varicella / zoster virus, influenza viruses (human, bird, swine, etc.), herpes simplex virus, adenovirus, enterovirus. , Rhinovirus, human papilloma virus (human papillomavirus), pox virus, coxsackie virus, herpes simplex virus, cytomegalovirus, EB virus, adenovirus, papilloma virus, JC virus, parvovirus, hepatitis B virus, hepatitis C virus , Lassa virus, feline calicivirus, norovirus, sapovirus, coronavirus, SARS virus, rubella virus, mumps virus, measles virus, RS virus, poliovirus Coxsackie virus, Echo virus, Marburg virus, Ebola virus, Yellow fever virus, Bunyaviridae virus, Rabies virus, Reoviridae virus, Rotavirus, Human immunodeficiency virus, Human T lymphophilic virus, Monkey immunodeficiency virus , STLV and the like. Examples of bacteria to which the method of the present invention can be applied include Gram-positive bacteria or Gram-negative bacteria such as Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli, Streptococcus, Neisseria gonorrhoeae, syphilis, meningococcus, tuberculosis, antibacterial Acid bacteria, Klebsiella (Klebsiella pneumoniae), Salmonella, Clostridium botulinum, Proteus, Bordetella pertussis, Vibrio parahaemolyticus, Citrobacter, Acinetobacter, Campylobacter, Enterobacter, Mycoplasma, Chlamydia, Clostridium and the like. Furthermore, examples of fungi to which the method of the present invention can be applied include Aspergillus, ringworm, Malassezia, and Candida.
本明細書において用いられる用語は、特定の実施態様を説明するために用いられるのであり、発明を限定する意図ではない。 The terminology used herein is for the purpose of describing particular embodiments and is not intended to be limiting of the invention.
また、本明細書において用いられる「含む」との用語は、文脈上明らかに異なる理解をすべき場合を除き、記載された事項(部材、ステップ、要素または数字等)が存在することを意図するものであり、それ以外の事項(部材、ステップ、要素または数字等)が存在することを排除しない。 In addition, the term “comprising” as used in this specification intends that there is a matter (a member, a step, an element, a number, or the like) described unless the context clearly requires different understanding. It does not exclude the presence of other items (members, steps, elements, numbers, etc.).
異なる定義が無い限り、ここに用いられるすべての用語(技術用語および科学用語を含む。)は、本発明が属する技術の当業者によって広く理解されるのと同じ意味を有する。ここに用いられる用語は、異なる定義が明示されていない限り、本明細書および関連技術分野における意味と整合的な意味を有するものとして解釈されるべきであり、理想化され、または、過度に形式的な意味において解釈されるべきではない。 Unless otherwise defined, all terms used herein (including technical and scientific terms) have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Terms used herein should be construed as having a meaning consistent with the meaning in this specification and the related technical field, unless otherwise defined, idealized, or overly formal. It should not be interpreted in a general sense.
本発明の実施態様は模式図を参照しつつ説明される場合があるが、模式図である場合、説明を明確にするために、誇張されて表現されている場合がある。 Embodiments of the present invention may be described with reference to schematic diagrams, but in the case of schematic diagrams, they may be exaggerated for clarity of explanation.
本明細書において、例えば、「1〜10%」と表現されている場合、当業者は、当該表現が、1、2、3、4、5、6、7、8、9、または10%を個別具体的に指すことを理解する。 In this specification, for example, when expressed as “1 to 10%”, those skilled in the art will recognize that the expression is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10%. Understand what it refers to individually.
本明細書において、成分含有量や数値範囲を示すのに用いられるあらゆる数値は、特に明示がない限り、用語「約」の意味を包含するものとして解釈される。例えば、「10倍」とは、特に明示がない限り、「約10倍」を意味するものと理解される。 In this specification, any numerical value used to indicate component content or numerical range is to be interpreted as including the meaning of the term “about” unless otherwise indicated. For example, “10 times” is understood to mean “about 10 times” unless otherwise specified.
本明細書中に引用される文献は、それらのすべての開示が、本明細書中に援用されているとみなされるべきであって、当業者は、本明細書の文脈に従って、本発明の精神および範囲を逸脱することなく、それらの先行技術文献における関連する開示内容を、本明細書の一部として援用して理解する。 References cited in this specification are to be regarded as the entire disclosure of which is hereby incorporated by reference, and those skilled in the art will recognize the spirit of the invention in accordance with the context of this specification. And without departing from the scope, the relevant disclosures in those prior art documents are incorporated and understood as part of the present specification.
以下において、本発明を、実施例を参照してより詳細に説明する。しかしながら、本発明はいろいろな態様により具現化することができ、ここに記載される実施例に限定されるものとして解釈されてはならない。 In the following, the present invention will be described in more detail with reference to examples. However, the invention can be embodied in various ways and should not be construed as limited to the embodiments set forth herein.
実施例1:本発明の二酸化塩素液剤の空間中における二酸化塩素濃度持続効果
<二酸化塩素液剤の準備>
本発明に係る二酸化塩素液剤は次のように調製された。まず、亜塩素酸ナトリウム25重量%溶液500mlに水17Lを加え、亜塩素酸ナトリウム水溶液を調製した。その後、二酸化塩素ガス2000ppmを溶解させた二酸化塩素水溶液1000mlを調製し、前記亜塩素酸ナトリウム水溶液と混合して撹拌した。次に、この溶液のpHが5.5〜6.0となる量のリン酸二水素ナトリウムおよび水を加えて撹拌した。このようにして、二酸化塩素ガス、亜塩素酸ナトリウム、及びリン酸二水素ナトリウムを含む二酸化塩素液剤20Lを得た(すなわち、亜塩素酸塩ナトリウムを0.625重量%、二酸化塩素ガスを100ppm含み、pHが5.5〜6.0である液剤を得た)。本実施例において、この二酸化塩素液剤を「本発明の二酸化塩素液剤」と呼ぶ。 Example 1 : Effect of sustaining chlorine dioxide concentration in the space of the chlorine dioxide solution of the present invention <Preparation of chlorine dioxide solution>
The chlorine dioxide solution according to the present invention was prepared as follows. First, 17 L of water was added to 500 ml of a 25 wt% sodium chlorite solution to prepare a sodium chlorite aqueous solution. Thereafter, 1000 ml of a chlorine dioxide aqueous solution in which 2000 ppm of chlorine dioxide gas was dissolved was prepared, mixed with the sodium chlorite aqueous solution and stirred. Next, sodium dihydrogen phosphate and water in such an amount that the pH of the solution was 5.5 to 6.0 were added and stirred. Thus, 20 L of chlorine dioxide solution containing chlorine dioxide gas, sodium chlorite, and sodium dihydrogen phosphate was obtained (that is, containing 0.625% by weight of sodium chlorite and 100 ppm of chlorine dioxide gas). And a liquid having a pH of 5.5 to 6.0 was obtained). In this embodiment, this chlorine dioxide solution is referred to as “the chlorine dioxide solution of the present invention”.
本実施例において比較例として用いた二酸化塩素ガス溶存液は、亜塩素酸塩ナトリウムに塩酸を加えることで発生させた二酸化塩素ガスを水に溶存させることによって調製された(すなわち、単純に二酸化塩素ガスを水に溶存させた溶液である)。本実施例において、この溶液を「二酸化塩素ガス溶存液」と呼ぶ。 The chlorine dioxide gas dissolved solution used as a comparative example in this example was prepared by dissolving chlorine dioxide gas generated by adding hydrochloric acid to sodium chlorite in water (that is, simply chlorine dioxide). It is a solution in which gas is dissolved in water). In this embodiment, this solution is referred to as “chlorine dioxide gas dissolved solution”.
<実験方法>
図1に本実施例の実験の概要を示した。1m3のチャンバーを準備し、本発明の二酸化塩素液剤、あるいは、二酸化塩素ガス溶存液をスプレーにより3回噴霧した。チャンバー内の空気を2個のファンにより撹拌しながら、ガス検知管により、チャンバー内の二酸化塩素ガス濃度を経時的に測定した。<Experiment method>
FIG. 1 shows an outline of the experiment of this example. A 1 m 3 chamber was prepared, and the chlorine dioxide solution of the present invention or the chlorine dioxide gas dissolved solution was sprayed three times by spraying. While stirring the air in the chamber with two fans, the chlorine dioxide gas concentration in the chamber was measured over time with a gas detector tube.
<結果>
実験結果を図2に示した。図2に示すとおり、二酸化塩素ガス溶存液を噴霧した場合、急激に二酸化塩素ガス濃度が減少し、1.5時間後には検出限界以下となった。一方、本発明の二酸化塩素液剤を噴霧した場合、約2時間までは、ガス濃度を維持し、その後緩やかに減少し、8時間後であっても初期濃度の約40%を維持した。<Result>
The experimental results are shown in FIG. As shown in FIG. 2, when the chlorine dioxide gas dissolved solution was sprayed, the chlorine dioxide gas concentration rapidly decreased and became below the detection limit after 1.5 hours. On the other hand, when the chlorine dioxide solution of the present invention was sprayed, the gas concentration was maintained until about 2 hours and then gradually decreased, and about 40% of the initial concentration was maintained even after 8 hours.
すなわち、驚くべきことに、本発明の二酸化塩素液剤は、空間中に噴霧された場合、その空間において、極めて長時間、二酸化塩素ガス濃度を維持する性質を有することが示された。 That is, it was surprisingly shown that the chlorine dioxide solution of the present invention has the property of maintaining the chlorine dioxide gas concentration in the space for a very long time when sprayed in the space.
実施例2:本発明の二酸化塩素液剤を利用した、医療廃棄物容器内の微生物の殺菌
<実験方法>
図3に本実施例の実験の概要を示した。なお、本実施例において用いられた二酸化塩素液剤は、実施例1に記載の方法と同じ方法で調製された二酸化塩素液剤である。 Example 2 : Sterilization of microorganisms in a medical waste container using the chlorine dioxide solution of the present invention <Experimental method>
FIG. 3 shows an outline of the experiment of this example. The chlorine dioxide solution used in this example is a chlorine dioxide solution prepared by the same method as that described in Example 1.
まず、病院等で使用される医療用廃棄物の容器(40L)(図4)を準備し、その容器中央に仕切りを設けた(容器の高さ2/3まで)。仕切られたエリアの一方に、大腸菌を付着させたシャーレを表向けに設置し(設置A)、もう一方のエリアに、同様のシャーレを裏向けに設置した(設置B)。83%エタノール、または、本発明の二酸化塩素液剤を設置Aのシャーレに向けて噴霧し、1時間後、設置A及び設置Bのシャーレから大腸菌を回収し、常法に従って生菌数を測定した。評価方法の概要を図5に示す。 First, a medical waste container (40L) (FIG. 4) used in a hospital or the like was prepared, and a partition was provided in the center of the container (up to 2/3 of the container height). A petri dish with E. coli attached to one side of the partitioned area was placed face up (Installation A), and the same petri dish was placed face down in the other area (Installation B). 83% ethanol or the chlorine dioxide solution of the present invention was sprayed onto the Petri dish of Installation A, and 1 hour later, E. coli was collected from the Petri dish of Installation A and Installation B, and the number of viable bacteria was measured according to a conventional method. An outline of the evaluation method is shown in FIG.
<結果>
実験結果を図6および図7に示した。図6および図7に示すように、設置Aでは83%エタノール、本発明の二酸化塩素液剤共に大腸菌を不活化したが、設置B(噴霧したエリアとは反対のエリア)では本発明の二酸化塩素液剤だけが大腸菌を不活化することができた。二酸化塩素液剤を噴霧した場合の容器内の二酸化塩素ガス濃度は3.3ppmであった。この結果は噴霧された二酸化塩素液剤から二酸化塩素ガスが発生し、そのガスにより、離れた場所にある裏向きに設置された大腸菌を不活化したことを示唆する。<Result>
The experimental results are shown in FIG. 6 and FIG. As shown in FIG. 6 and FIG. 7, in the installation A, both 83% ethanol and the chlorine dioxide solution of the present invention were inactivated, but in the installation B (the area opposite to the sprayed area), the chlorine dioxide solution of the present invention. Only was able to inactivate E. coli. The chlorine dioxide gas concentration in the container when sprayed with the chlorine dioxide solution was 3.3 ppm. This result suggests that chlorine dioxide gas was generated from the sprayed chlorine dioxide solution, and that gas inactivated the Escherichia coli placed in the back.
すなわち、本発明の二酸化塩素液剤によれば、液剤が直接適用された箇所の微生物を消毒できるだけではなく、液剤が適用された容器内の二酸化塩素濃度が長期間に渡って維持される効果により、直接液剤が適用されていない箇所まで(例えば、液剤が直接届かない容器の隅や、複雑な構造をした廃棄物の隅々まで)消毒することが可能となる。また、本発明の二酸化塩素液剤によれば、消毒の対象となる医療廃棄物へ直接適用せずとも、医療廃棄物が収納された容器の特定の空間に液剤を適用するだけで、間接的に医療廃棄物の隅々まで消毒効果を発揮させることができるため、医療従事者等が医療廃棄物に接触するリスクを最小限に抑えた消毒方法を提供することができる。 That is, according to the chlorine dioxide solution of the present invention, not only can the microorganisms at the location where the solution is directly applied be disinfected, but also the effect of maintaining the chlorine dioxide concentration in the container to which the solution is applied over a long period of time, It is possible to disinfect a portion where the liquid agent is not directly applied (for example, to a corner of a container where the liquid agent does not reach directly or to a corner of waste having a complicated structure). Moreover, according to the chlorine dioxide solution of the present invention, it is not necessary to directly apply the medical waste to the medical waste to be disinfected, but only by applying the liquid to a specific space of the container in which the medical waste is stored. Since the sterilizing effect can be exerted to every corner of the medical waste, it is possible to provide a sterilizing method that minimizes the risk of medical workers and the like coming into contact with the medical waste.
例えば、新型インフルエンザ、エボラ出血熱、MERS等の致死率の高い感染症が流行した場合、感染源の付着の疑いのある廃棄物が短期間に大量に発生することが予測される。本発明の方法を、それらの廃棄物を収納する容器等に適用することで、より簡便かつ安全に感染源を封じ込める(あるいは、廃棄物容器から有害微生物が拡散するリスクを低減させる)ことが可能となる。 For example, when an infectious disease with a high lethality such as a new type of influenza, Ebola hemorrhagic fever, MERS, etc. is prevalent, it is predicted that a large amount of waste that is suspected of attaching an infectious source will be generated in a short time. By applying the method of the present invention to containers for storing those wastes, it is possible to contain infection sources more simply and safely (or reduce the risk of harmful microorganisms spreading from waste containers). It becomes.
実施例3:本発明の二酸化塩素液剤を利用した、医療廃棄物容器内のウイルスの不活化
<材料および方法>
試験ウイルス:feline calicivirus(FCV,F9,ATCC VR−782)(ノロウイルスの代替として使用)
ホスト細胞:Crandell Reese feline kidney cells(CRFK,ATCC CCL−94)
二酸化塩素ガス発生源:実施例1に記載の方法と同じ方法で調製された二酸化塩素液剤 Example 3 : Inactivation of viruses in medical waste containers using the chlorine dioxide solution of the present invention <Materials and methods>
Test virus: feline calicivirus (FCV, F9, ATCC VR-782) (used as an alternative to norovirus)
Host cell: Crandell Reese felt kidney cells (CRFK, ATCC CCL-94)
Chlorine dioxide gas source: chlorine dioxide solution prepared by the same method as described in Example 1
実験器具
・1m3チャンバー(注文品)
・96穴マイクロプレート(353072,FALCON)
・96穴ディープウエルプレート(BM6030,BM Bio)
・Reagent Reservoirs/Tip−Tub(022265806,eppendorf)
・AC FAN(MU825S−13N,ORIX)
・ガラスシャーレ(305−02,Top)
・セルスクレーパー(179693,Thermo)
・気体検知管(No.23L二酸化塩素,ガステック)Laboratory instruments · 1m 3 chamber (orders)
・ 96-well microplate (353072, FALCON)
・ 96-well deep well plate (BM6030, BM Bio)
・ Reagent Reservoirs / Tip-Tub (022265806, eppendorf)
・ AC FAN (MU825S-13N, ORIX)
・ Glass Petri dish (305-02, Top)
・ Cell scraper (179963, Thermo)
・ Gas detector tube (No. 23L chlorine dioxide, GASTECH)
実験機器
・CO2インキュベーター(MCO−175AICUVH,PANASONIC)
・温湿度計(TR−72wf,T&D)Laboratory equipment / CO2 incubator (MCO-175AICUVH, PANASONIC)
・ Temperature and humidity meter (TR-72wf, T & D)
実験材料
・Dulbecco’s Modified Eagle’s Medium−high glucose(D−MEM,D5796,SIGMA)
・Dulbecco’s Phosphate Buffered Saline(D8537,SIGMA)
・0.25% Trypsin Solution(35555−54,Nacalai tesque)
・Fetal Bovine Serum(FBS,30−2020,ATCC)
・EDTA Disodium Salt 2% Solution in PBS Saline(2820549,MP)Experimental Materials ・ Dulbecco's Modified Eagle's Medium-high glucose (D-MEM, D5796, SIGMA)
・ Dulbecco's Phosphate Buffered Saline (D8537, SIGMA)
・ 0.25% Trypsin Solution (35555-54, Nacalai quest)
・ Fetal Bovine Serum (FBS, 30-2020, ATCC)
・ EDTA Disodium Salt 2% Solution in PBS Saline (2820549, MP)
ウイルス浮遊液の調整:
−80℃に冷凍保存していたFeline calicivirus(108.5TCID50/50μL)を1%FBS溶液で107−7.5TCID50/50μLまで希釈したものをウイルス浮遊液とした。Preparation of virus suspension:
A material obtained by diluting Feline Calicivirus that had been frozen to -80 ° C. The (10 8.5 TCID50 / 50μL) in 1% FBS solution until 10 7-7.5 TCID50 / 50μL was virus suspension.
ウイルス回収液(中和液):
1mMチオ硫酸ナトリウム溶液(*)含有2%FBS D−MEM(抗+)120μLをウイルス回収液とした。
(*)1mMチオ硫酸ナトリウム溶液は0.1ppmvの二酸化塩素ガスを問題なく中和できる濃度である。Virus recovery solution (neutralization solution):
120 μL of 2% FBS D-MEM (anti- +) containing 1 mM sodium thiosulfate solution (*) was used as the virus recovery solution.
(*) 1 mM sodium thiosulfate solution has a concentration capable of neutralizing 0.1 ppmv chlorine dioxide gas without any problem.
実験方法(図8参照):
1%FBS(ウシ胎児血清)添加のネコカリシウイルス浮遊液(107〜7.5TCID50/50μL)を1μl滴下したシャーレを1m3チャンバー内のBの箇所に設置した。設置後、本発明の二酸化塩素液剤を、設置したシャーレから約70cm離れた場所に噴霧した。滴下したFCVを、本発明の二酸化塩素液剤の噴霧により発生する二酸化塩素ガスに各時間暴露させ中和した後、ウイルスを回収し各時間のウイルス感染価を求め評価した。同様に、本発明の二酸化塩素液剤のかわりに水を噴霧した場合をコントロールとした。Experimental method (see FIG. 8):
A petri dish in which 1 μl of a feline calicivirus suspension (10 7 to 7.5 TCID 50/50 μL) supplemented with 1% FBS (fetal bovine serum) was dropped was placed at a position B in a 1 m 3 chamber. After the installation, the chlorine dioxide solution of the present invention was sprayed to a place about 70 cm away from the installed petri dish. The dropped FCV was exposed to and neutralized with chlorine dioxide gas generated by spraying the chlorine dioxide solution of the present invention for each time, and then the virus was recovered and the virus infectivity titer at each time was determined and evaluated. Similarly, the case where water was sprayed instead of the chlorine dioxide solution of the present invention was used as a control.
二酸化塩素ガス濃度:
1m3チャンバー内の二酸化塩素ガス濃度は検知管によって測定した。Chlorine dioxide gas concentration:
The chlorine dioxide gas concentration in the 1 m 3 chamber was measured with a detector tube.
<結果>
実験は2回にわたって実施された。
1回目の実験の結果を図9に示す。1回目の実験では、本発明の二酸化塩素液剤を噴霧した場合、チャンバー内の二酸化塩素ガス濃度は平均0.1ppmv(min;0.075ppmv,max;0.1ppmv)となった。本発明の二酸化塩素液剤の代わりに水を噴霧したコントロールでは、噴霧10分後のウイルスタイターは106.3TCID50/50μLであったが、本発明の二酸化塩素液剤を噴霧した場合は102.8TCID50/50μLとなった(3.5log10低減した)。また、噴霧15分後においては、コントロールにおけるウイルスタイターは104.5TCID50/50μLであったが、本発明の二酸化塩素液剤を噴霧した場合、102.3TCID50/50μLとなった(2.2log10低減)。噴霧30分後においては、コントロールにおけるウイルスタイターは105.5TCID50/50μLであったが、本発明の二酸化塩素液剤を噴霧した場合、101.0TCID50/50μLとなった(4.5log10低減)。<Result>
The experiment was performed twice.
The results of the first experiment are shown in FIG. In the first experiment, when the chlorine dioxide solution of the present invention was sprayed, the chlorine dioxide gas concentration in the chamber averaged 0.1 ppmv (min; 0.075 ppmv, max; 0.1 ppmv). In the control in which water was sprayed instead of the chlorine dioxide solution of the present invention, the virus titer after 10 minutes of spraying was 10 6.3 TCID 50/50 μL, but 10 2 when the chlorine dioxide solution of the present invention was sprayed. .8 TCID 50/50 μL (reduced by 3.5 log 10 ). Further, after 15 minutes of spraying, the virus titer in the control was 10 4.5 TCID 50/50 μL, but when sprayed with the chlorine dioxide solution of the present invention, it became 10 2.3 TCID 50/50 μL ( 2.2 log 10 reduction). At 30 minutes after spraying, the virus titer in the control was 10 5.5 TCID 50/50 μL, but when sprayed with the chlorine dioxide solution of the present invention, it was 10 1.0 TCID 50/50 μL (4. 5 log 10 reduction).
2回目の実験結果を図10に示す。2回目の実験では、本発明の二酸化塩素液剤を噴霧した場合、チャンバー内の二酸化塩素ガス濃度は平均0.1ppmv(min;0.1ppmv,max;0.2ppmv)となった。本発明の二酸化塩素液剤の代わりに水を噴霧したコントロールでは、噴霧10分後のウイルスタイターは105.5TCID50/50μLであったが、本発明の二酸化塩素液剤を噴霧した場合は100.8TCID50/50μLとなった(4.7log10低減)。また、噴霧15分後にておいは、コントロールにおけるウイルスタイターは104.3TCID50/50μLであったが、本発明の二酸化塩素液剤を噴霧した場合、101.7TCID50/50μLとなった(2.6log10低減)。噴霧30分後においては、コントロールにおけるウイルスタイターは103.9TCID50/50μLであったが、本発明の二酸化塩素液剤を噴霧した場合は100.5TCID50/50μLとなった(3.4log10低減)。The results of the second experiment are shown in FIG. In the second experiment, when the chlorine dioxide solution of the present invention was sprayed, the chlorine dioxide gas concentration in the chamber averaged 0.1 ppmv (min; 0.1 ppmv, max; 0.2 ppmv). In the control in which water was sprayed instead of the chlorine dioxide solution of the present invention, the virus titer after 10 minutes of spraying was 10 5.5 TCID 50/50 μL, but when the chlorine dioxide solution of the present invention was sprayed, the virus titer was 10 0. .8 TCID 50/50 μL (4.7 log 10 reduction). Also, the place for 15 minutes after spraying, the virus titer in the control was 10 4.3 TCID 50 / 50μL, if a chlorine dioxide solution of the present invention were sprayed became 10 1.7 TCID 50 / 50μL (2.6 log 10 reduction). At 30 minutes after spraying, the virus titer in the control was 10 3.9 TCID 50/50 μL, but when sprayed with the chlorine dioxide solution of the present invention, it was 10 0.5 TCID 50/50 μL (3. 4 log 10 reduction).
以上のことから、本発明は、細菌だけでなく、ウイルスにおいても適用可能であることが示された。
From the above, it was shown that the present invention can be applied not only to bacteria but also to viruses.
Claims (10)
前記医療廃棄物容器内に二酸化塩素ガスおよび亜塩素酸塩を含む液剤を適用する工程を含み、
前記液剤は、前記二酸化塩素ガスを徐放放出する組成を備えることを特徴とする、
方法。A method for treating a medical waste container including medical waste accompanied by harmful microorganisms,
Applying a liquid agent containing chlorine dioxide gas and chlorite in the medical waste container,
The liquid agent comprises a composition that releases the chlorine dioxide gas gradually,
Method.
前記液剤の組成として、前記液剤には、10〜2000ppmの二酸化塩素ガス、0.05重量%〜10重量%の亜塩素酸塩の濃度が含まれており、かつ、前記液剤のpHは4.5〜6.5の範囲内に調製されていることを特徴とする、
方法。It is a processing method of the medical waste container according to claim 1,
As the composition of the solution, the solution contains a concentration of 10 to 2000 ppm of chlorine dioxide gas, 0.05 wt% to 10 wt% of chlorite, and the pH of the solution is 4. It is prepared in the range of 5 to 6.5,
Method.
前記液剤の適用が、前記液剤の医療廃棄物容器内への噴霧または、前記液剤を含む容器の医療廃棄物容器内への設置によることを特徴とする、
方法。It is a processing method of the medical waste container according to claim 1 or 2,
The application of the liquid agent is by spraying the liquid agent into a medical waste container or by installing the container containing the liquid agent in a medical waste container,
Method.
前記有害微生物が感染性微生物である、
方法。It is a processing method of the medical waste container according to any one of claims 1 to 3,
The harmful microorganism is an infectious microorganism,
Method.
前記液剤が、50〜1000ppmの二酸化塩素ガスを含む、
方法。It is a processing method of the medical waste container according to any one of claims 1 to 4,
The liquid agent contains 50 to 1000 ppm of chlorine dioxide gas.
Method.
前記液剤が、0.1重量%〜5.0重量%の亜塩素酸塩を含む、
方法。It is a processing method of the medical waste container according to any one of claims 1 to 5,
The solution comprises 0.1 wt% to 5.0 wt% chlorite;
Method.
前記液剤のpHが、5.5〜6.0の範囲内である、
方法。It is a processing method of the medical waste container according to any one of claims 1 to 6,
The pH of the solution is in the range of 5.5 to 6.0.
Method.
前記液剤の適用が、少なくとも一部の前記有害微生物に対し、前記液剤が直接的に接触しないことを特徴とする、
方法。It is a processing method of the medical waste container according to any one of claims 1 to 7,
Application of the liquid agent is characterized in that the liquid agent does not directly contact at least a part of the harmful microorganisms,
Method.
前記液剤の適用が、すべての前記有害微生物に対し、前記液剤が直接的に接触しないことを特徴とする、
方法。A method for treating a medical waste container according to claim 8,
Application of the solution is characterized in that the solution is not in direct contact with all the harmful microorganisms,
Method.
前記処理が、前記有害微生物の拡散を低減することを特徴とする、
方法。It is a processing method of the medical waste container according to any one of claims 1 to 9,
The treatment reduces the diffusion of the harmful microorganisms,
Method.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015232008 | 2015-11-27 | ||
JP2015232008 | 2015-11-27 | ||
PCT/JP2016/084516 WO2017090570A1 (en) | 2015-11-27 | 2016-11-21 | Medical waste container treatment method |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020212017A Division JP7204232B2 (en) | 2015-11-27 | 2020-12-22 | How to dispose of medical waste containers |
Publications (1)
Publication Number | Publication Date |
---|---|
JPWO2017090570A1 true JPWO2017090570A1 (en) | 2018-09-13 |
Family
ID=58763470
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017552409A Pending JPWO2017090570A1 (en) | 2015-11-27 | 2016-11-21 | Treatment method for medical waste containers |
JP2020212017A Active JP7204232B2 (en) | 2015-11-27 | 2020-12-22 | How to dispose of medical waste containers |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020212017A Active JP7204232B2 (en) | 2015-11-27 | 2020-12-22 | How to dispose of medical waste containers |
Country Status (6)
Country | Link |
---|---|
JP (2) | JPWO2017090570A1 (en) |
KR (1) | KR102601062B1 (en) |
CN (1) | CN108367091A (en) |
HK (1) | HK1252261A1 (en) |
TW (2) | TW202233258A (en) |
WO (1) | WO2017090570A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220160916A1 (en) * | 2019-04-04 | 2022-05-26 | Nitta Corporation | Decontamination device and system |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001029440A (en) * | 1999-07-21 | 2001-02-06 | San Seal:Kk | Sterilizing/deodorizing method for repeatedly used medical instrument, clothing or the like |
JP2003075820A (en) * | 2001-08-30 | 2003-03-12 | Samsung Electronics Co Ltd | Color filter plate and thin film transistor plate for liquid crystal display device and manufacturing method therefor |
JP2013075820A (en) * | 2007-03-15 | 2013-04-25 | Taiko Pharmaceutical Co Ltd | Method for maintaining chlorine dioxide concentration |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5190725A (en) * | 1990-04-19 | 1993-03-02 | Winfield Industries | Chemical treatment of an infectious waste |
JPH08129B2 (en) | 1991-07-29 | 1996-01-10 | 藤田 佐内 | Medical waste treatment method |
JP3345049B2 (en) | 1992-07-22 | 2002-11-18 | 義昭 波多野 | Medical waste treatment method and apparatus therefor |
JP3492423B2 (en) | 1994-07-19 | 2004-02-03 | 佐内 藤田 | Method and apparatus for sterilizing and deodorizing medical waste |
JP3110724B2 (en) * | 1997-11-28 | 2000-11-20 | ビジネスプラン株式会社 | Pure chlorine dioxide solution, gel composition and foamable composition containing the same, and container for containing them |
JP2000063217A (en) * | 1998-06-11 | 2000-02-29 | Dmc Network:Kk | Sustained release chlorine dioxide-containing liquid agent having excellent preservation stability |
JP2006263173A (en) * | 2005-03-24 | 2006-10-05 | San Seal:Kk | Device for generating high concentration germicidal gas, and circulation type sterilizing method with the germicidal gas |
US20100084604A1 (en) * | 2007-03-15 | 2010-04-08 | Taiko Pharmaceutical Co., Ltd. | Composition for stabilizing chlorine dioxide |
-
2016
- 2016-11-21 CN CN201680068097.7A patent/CN108367091A/en active Pending
- 2016-11-21 WO PCT/JP2016/084516 patent/WO2017090570A1/en active Application Filing
- 2016-11-21 KR KR1020187014252A patent/KR102601062B1/en active IP Right Grant
- 2016-11-21 JP JP2017552409A patent/JPWO2017090570A1/en active Pending
- 2016-11-24 TW TW111115846A patent/TW202233258A/en unknown
- 2016-11-24 TW TW105138640A patent/TWI795348B/en active
-
2018
- 2018-09-07 HK HK18111565.2A patent/HK1252261A1/en unknown
-
2020
- 2020-12-22 JP JP2020212017A patent/JP7204232B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001029440A (en) * | 1999-07-21 | 2001-02-06 | San Seal:Kk | Sterilizing/deodorizing method for repeatedly used medical instrument, clothing or the like |
JP2003075820A (en) * | 2001-08-30 | 2003-03-12 | Samsung Electronics Co Ltd | Color filter plate and thin film transistor plate for liquid crystal display device and manufacturing method therefor |
JP2013075820A (en) * | 2007-03-15 | 2013-04-25 | Taiko Pharmaceutical Co Ltd | Method for maintaining chlorine dioxide concentration |
Also Published As
Publication number | Publication date |
---|---|
TW202233258A (en) | 2022-09-01 |
KR102601062B1 (en) | 2023-11-10 |
KR20180088810A (en) | 2018-08-07 |
JP7204232B2 (en) | 2023-01-16 |
CN108367091A (en) | 2018-08-03 |
WO2017090570A1 (en) | 2017-06-01 |
HK1252261A1 (en) | 2019-05-24 |
TW201726182A (en) | 2017-08-01 |
TWI795348B (en) | 2023-03-11 |
JP2021045753A (en) | 2021-03-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Bhardwaj et al. | UVC-based photoinactivation as an efficient tool to control the transmission of coronaviruses | |
Chiappa et al. | The efficacy of ultraviolet light-emitting technology against coronaviruses: a systematic review | |
CN103796515B (en) | Stabilized hypohalous acid solutions | |
KR101426570B1 (en) | Method of controlling floating virus infection | |
JP6144413B2 (en) | Hydrochloric acid-containing virus killing agent | |
Kindermann et al. | Virus disinfection for biotechnology applications: Different effectiveness on surface versus in suspension | |
Krishnan et al. | Evaluation of a dry fogging system for laboratory decontamination | |
JP7204232B2 (en) | How to dispose of medical waste containers | |
Rowan et al. | Efficacy of frontline chemical biocides and disinfection approaches for inactivating SARS-CoV-2 variants of concern that cause coronavirus disease with the emergence of opportunities for green eco-solutions | |
JP6243482B2 (en) | Method for inactivating pathogenic microorganisms | |
Sun et al. | Effect of chlorine dioxide on avian influenza A (H7N9) virus | |
KR102127417B1 (en) | Compositions for sterilization and disinfection using hydrogen peroxide | |
Sharma et al. | Achieving sterility in biomedical and pharmaceutical products (part-I): thermal, chemical, and filtration sterilization | |
Yee et al. | Efficacy of chlorine dioxide as a disinfectant | |
Brady | Evaluating Chlorine Dioxide Gas as an Antiviral Agent: Insights from the Development, Optimization, and Application of a MS2 Bacteriophage Model System | |
JP2008214297A (en) | Antiviral agent | |
Sanofer | Glass Bead Steriliser Used As Chair Side Sterilisation in the Dentistry-A Research Article | |
Barnes et al. | Action of physical and chemical agents on microorganisms | |
Heninger et al. | Decontamination of Bacillus anthracis spores: Evaluation of various disinfectants | |
McDonnell et al. | Amsco® V-PRO™ 1: A new low temperature sterilisation system | |
Watanabe et al. | Virucidal activity of olanexidine gluconate against SARS-CoV-2 | |
Earar et al. | The implications of the specialization of asepsis and antisepsis methods in medical assistance in different systemic pathologies | |
Khou-Bouvattier et al. | Effect of virucidal components on highly pathogenic viral agents | |
Bocklagea et al. | Evaluation of Hypochlorous Acid Fogging: An Alternative Disinfection Method | |
Gupta | STERILIZATION AND DISINFECTION |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190910 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200714 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200825 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20200923 |